These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 22955373

  • 1. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G, Vervliet T, Akl H, Bultynck G.
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [Abstract] [Full Text] [Related]

  • 2. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
    Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G.
    Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
    [Abstract] [Full Text] [Related]

  • 3. Bcl-xL acts as an inhibitor of IP3R channels, thereby antagonizing Ca2+-driven apoptosis.
    Rosa N, Ivanova H, Wagner LE, Kale J, La Rovere R, Welkenhuyzen K, Louros N, Karamanou S, Shabardina V, Lemmens I, Vandermarliere E, Hamada K, Ando H, Rousseau F, Schymkowitz J, Tavernier J, Mikoshiba K, Economou A, Andrews DW, Parys JB, Yule DI, Bultynck G.
    Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
    [Abstract] [Full Text] [Related]

  • 4. Tracing the evolutionary history of Ca2+-signaling modulation by human Bcl-2: Insights from the Capsaspora owczarzaki IP3 receptor ortholog.
    Rosa N, Shabardina V, Ivanova H, Sebé-Pedrós A, Yule DI, Bultynck G.
    Biochim Biophys Acta Mol Cell Res; 2021 Nov; 1868(12):119121. PubMed ID: 34400171
    [Abstract] [Full Text] [Related]

  • 5. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
    Akl H, Monaco G, La Rovere R, Welkenhuyzen K, Kiviluoto S, Vervliet T, Molgó J, Distelhorst CW, Missiaen L, Mikoshiba K, Parys JB, De Smedt H, Bultynck G.
    Cell Death Dis; 2013 May 16; 4(5):e632. PubMed ID: 23681227
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output.
    Ivanova H, Wagner LE, Tanimura A, Vandermarliere E, Luyten T, Welkenhuyzen K, Alzayady KJ, Wang L, Hamada K, Mikoshiba K, De Smedt H, Martens L, Yule DI, Parys JB, Bultynck G.
    Cell Mol Life Sci; 2019 Oct 16; 76(19):3843-3859. PubMed ID: 30989245
    [Abstract] [Full Text] [Related]

  • 8. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H, Ritaine A, Wagner L, Luyten T, Shapovalov G, Welkenhuyzen K, Seitaj B, Monaco G, De Smedt H, Prevarskaya N, Yule DI, Parys JB, Bultynck G.
    Oncotarget; 2016 Aug 23; 7(34):55704-55720. PubMed ID: 27494888
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.
    Vervliet T, Parys JB, Bultynck G.
    Biochem Soc Trans; 2015 Jun 23; 43(3):396-404. PubMed ID: 26009182
    [Abstract] [Full Text] [Related]

  • 10. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
    Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, Parys JB, Leybaert L, Bultynck G.
    Cell Death Differ; 2012 Feb 23; 19(2):295-309. PubMed ID: 21818117
    [Abstract] [Full Text] [Related]

  • 11. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
    Schulman JJ, Wright FA, Kaufmann T, Wojcikiewicz RJH.
    J Biol Chem; 2013 Aug 30; 288(35):25340-25349. PubMed ID: 23884412
    [Abstract] [Full Text] [Related]

  • 12. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.
    Monaco G, Decrock E, Arbel N, van Vliet AR, La Rovere RM, De Smedt H, Parys JB, Agostinis P, Leybaert L, Shoshan-Barmatz V, Bultynck G.
    J Biol Chem; 2015 Apr 03; 290(14):9150-61. PubMed ID: 25681439
    [Abstract] [Full Text] [Related]

  • 13. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP, Barr P, Yee VC, Distelhorst CW.
    Biochim Biophys Acta; 2009 Jun 03; 1793(6):971-8. PubMed ID: 19056433
    [Abstract] [Full Text] [Related]

  • 14. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.
    FEBS J; 2018 Jan 03; 285(1):127-145. PubMed ID: 29131545
    [Abstract] [Full Text] [Related]

  • 15. Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.
    Vervliet T, Lemmens I, Welkenhuyzen K, Tavernier J, Parys JB, Bultynck G.
    Biochem Biophys Res Commun; 2015 Jul 31; 463(3):174-9. PubMed ID: 25957473
    [Abstract] [Full Text] [Related]

  • 16. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 31; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 17. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, Mignery GA, Parys JB, De Smedt H, Distelhorst CW.
    Mol Cell; 2008 Jul 25; 31(2):255-65. PubMed ID: 18657507
    [Abstract] [Full Text] [Related]

  • 18. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
    Akl H, La Rovere RM, Janssens A, Vandenberghe P, Parys JB, Bultynck G.
    Int J Dev Biol; 2015 Jul 25; 59(7-9):391-8. PubMed ID: 26260683
    [Abstract] [Full Text] [Related]

  • 19. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
    Monaco G, Decrock E, Nuyts K, Wagner LE, Luyten T, Strelkov SV, Missiaen L, De Borggraeve WM, Leybaert L, Yule DI, De Smedt H, Parys JB, Bultynck G.
    PLoS One; 2013 Jul 25; 8(8):e73386. PubMed ID: 24137498
    [Abstract] [Full Text] [Related]

  • 20. Profiling of the Bcl-2/Bcl-X(L)-binding sites on type 1 IP(3) receptor.
    Monaco G, Beckers M, Ivanova H, Missiaen L, Parys JB, De Smedt H, Bultynck G.
    Biochem Biophys Res Commun; 2012 Nov 09; 428(1):31-5. PubMed ID: 23058917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.